SCHEMBL4489367

SCHEMBL4489367

O=C(C(=O)c1cccc2ccc(OCc3ccccc3)cc12)c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.50
PLAU P00749 1/20 0.50
PLAT P00750 1/20 0.50
PTPRC P08575 1/20 0.48
PTPN1 P18031 1/20 0.48
ALOX5 P09917 1/20 0.48
MAPT P10636 3/20 0.47
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP3A4 P08684 1/20 0.47
NR4A2 P43354 2/20 0.46
NR4A1 P22736 1/20 0.46
NR4A3 Q92570 1/20 0.46
GPR132 Q9UNW8 1/20 0.45
MAOB P27338 3/20 0.44
PARP10 Q53GL7 1/20 0.44
GRK2 P25098 1/20 0.44
GRK3 P35626 1/20 0.44
MCL1 Q07820 1/20 0.44
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414966 0.81 MRGPRX4 (0.60) MRGPRX4PLAUPLATALOX5ALDH1A1
SCHEMBL8792578 0.80 NR4A2 (0.67) MRGPRX4PTPN1ALDH1A1NR4A2GPR132
SCHEMBL8597245 0.80 HIF1A (0.52) MRGPRX4PLAUPLATALOX5MAPT
SCHEMBL8797722 0.76 SGMS2 (0.53) MAPTALDH1A1SMN1; SMN2NPC1
SCHEMBL8596749 0.75 ALOX5 (0.51) MRGPRX4PLAUPLATPTPRCPTPN1
SCHEMBL27639367 0.74 ABCB1 (0.58) PLAUPLATALOX5ALDH1A1SMN1; SMN2
SCHEMBL8596746 0.73 ALOX5 (0.48) MRGPRX4PLAUPLATALOX5SMN1; SMN2
SCHEMBL8596757 0.73 ALOX5 (0.48) MRGPRX4PLAUPLATALOX5SMN1; SMN2
SCHEMBL38662923 0.72 ALOX5 (0.65) MRGPRX4PLAUPLATALOX5CYP3A4
SCHEMBL10606515 0.70 ALOX5 (0.67) MRGPRX4PLAUPLATALOX5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; IRM LLC (BM) 2009-10-15 US disclosed
US-7569593-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-08-04 US disclosed
EP-1670780-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-12-17 EP disclosed
EP-1670780-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-06-21 EP disclosed
US-20050209285-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-09-22 US disclosed
WO-2005030151-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258910-A1 benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; PDGFRA, RAF1, FLT1 MRGPRX4 2432/4885PLAU 3885/4885PLAT 1650/4885
US-20050209285-A1 Compounds and compositions as protein kinase inhibitors LCK, RAF1, MAP3K1 MRGPRX4 2813/4885PLAU 3662/4885PLAT 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.